SCHEMBL7101753

SCHEMBL7101753

Cc1nc(C2=CCCc3c(N)cccc32)cn1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 2/20 0.38
SMARCA4 P51532 2/20 0.38
PBRM1 Q86U86 2/20 0.38
SCN3A Q9NY46 8/20 0.36
SCN4A P35499 4/20 0.36
SCN9A Q15858 3/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
PARP1 P09874 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
SCN5A Q14524 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
PDK4 Q16654 1/20 0.33
GRM5 P41594 2/20 0.32
GRM1 Q13255 1/20 0.32
F12 P00748 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7100197 0.84 PARP1 (0.35) SMARCA2SMARCA4PBRM1SCN3ASCN4A
SCHEMBL25081186 0.71 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1SCN3ASCN4A
SCHEMBL31525447 0.67 PTPN1 (0.41) SCN3ASCN4ASCN9AHSP90AA1HSP90AB1
SCHEMBL7103436 0.67 P2RX3 (0.36) SMARCA2SMARCA4PBRM1SCN9APARP1
SCHEMBL24176885 0.63 PARP1 (0.36) SMARCA2SMARCA4PBRM1HSP90AA1HSP90AB1
SCHEMBL18007742 0.63 SCN3A (0.50) SMARCA2SMARCA4PBRM1SCN3ASCN4A
SCHEMBL29887044 0.63 GPR119 (0.43) SCN3ASCN9AHSP90AA1HSP90AB1SCN5A
SCHEMBL21964515 0.63 L3MBTL1 (0.46) SCN3ASCN4ASCN9AHSP90AA1HSP90AB1
SCHEMBL256728 0.62 UCHL1 (0.51) GPR119
SCHEMBL21055656 0.61 ACLY (0.47) SCN3ASCN4ASCN9AHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A SMARCA2 638/4885SMARCA4 583/4885PBRM1 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.